Dr. Reddy's Laboratories (500124) Aandelenoverzicht
Dr. Reddy's Laboratories Limited is, samen met haar dochterondernemingen, wereldwijd actief als een geïntegreerd farmaceutisch bedrijf. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 5/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor 500124 uit onze risicocontroles.
500124 Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Dr. Reddy's Laboratories Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹1,353.75 |
| 52 Week Hoogtepunt | ₹1,414.40 |
| 52 Week Laag | ₹1,149.00 |
| Bèta | 0.26 |
| 1 maand verandering | 5.94% |
| 3 maanden verandering | 13.62% |
| 1 Jaar Verandering | 5.44% |
| 3 jaar verandering | 31.07% |
| 5 jaar verandering | 24.55% |
| Verandering sinds IPO | 39,669.33% |
Recent nieuws en updates
Narratiefupdate • Jun 25
500124: Lower Profitability Expectations Will Restrain Future Share Price Upside
Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.
Narratiefupdate • Jun 05
500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes
Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.Recent updates
Narratiefupdate • Jun 25
500124: Lower Profitability Expectations Will Restrain Future Share Price Upside
Analysts have adjusted their price target for Dr. Reddy's Laboratories from ₹1,024 to ₹1,040, reflecting updated views on revenue growth, profit margins and future P/E assumptions in their valuation work. What's in the News Dr. Reddy's Laboratories has scheduled a board meeting for July 22, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.Narratiefupdate • Jun 05
500124: Diabetes And Oncology Launches Will Drive Future Upside Despite GST Disputes
Analysts have lifted their price target on Dr. Reddy's Laboratories from ₹1,615 to about ₹1,679, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models. What's in the News R-Pharm Group and Dr. Reddy's agreed to introduce the anticancer drug toripalimab in Russia, with all finished dosage production to be localized at R-Pharm facilities, after Dr. Reddy's secured commercialization rights across 21 countries and launched the drug in India and Australia.
Narratiefupdate • May 22
500124: Fair Outlook Will Balance Injectable Diabetes Launches And Compliance Developments
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories up from ₹1,314 to about ₹1,332. This change reflects updated assumptions around revenue growth, profit margins and future P/E expectations.Narratiefupdate • May 03
500124: Future Tax Compliance And Regulatory Setbacks Will Curb Share Price Upside
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,024, explaining that small adjustments to revenue growth, profit margin and future P/E assumptions did not materially change their overall price target view. What's in the News Health Canada granted Dr. Reddy's a Notice of Compliance for its generic Semaglutide Injection, allowing commercialization and sale in Canada.Narratiefupdate • Apr 19
500124: Future Tax And Regulatory Compliance Issues Will Limit Upside Potential
Analysts have revised their price target for Dr. Reddy's Laboratories to ₹1,024, reflecting updated assumptions of higher revenue growth of 5.96%, a profit margin of 16.95% and a lower future P/E of 17.43x. What's in the News Launch of Obeda, an injectable semaglutide for type 2 diabetes in India, following Drugs Controller General of India approval for generic semaglutide.Narratiefupdate • Apr 05
500124: Fair Outlook Will Balance Biosimilar Opportunity And Compliance Developments
Analysts have increased their price target on Dr. Reddy's Laboratories by about ₹13 to ₹1,314, citing updated assumptions that include a different discount rate, revised revenue growth and profit margin estimates, and an adjusted future P/E multiple. What's in the News Board meeting scheduled for March 24, 2026, to amend the Code of Practices and Procedures for Fair Disclosures of Un published Price Sensitive Information, signaling a focus on disclosure norms and compliance (company filing).Narratiefupdate • Mar 21
500124: Biosimilar Pipeline Progress Will Drive Future Upside Despite GST Disputes
Analysts have maintained their price target for Dr. Reddy's Laboratories at ₹1,615. This reflects only minor adjustments to revenue growth, profit margin and forward P/E assumptions, rather than a change in the overall valuation view.Narratiefupdate • Mar 07
500124: Biosimilar Approvals Will Drive Future Upside Despite Regulatory And Tax Overhang
Analysts have kept their price target for Dr. Reddy's Laboratories unchanged at ₹1,615, citing only marginal tweaks to revenue growth, profit margin and forward P/E assumptions that do not materially alter their valuation view. What's in the News The USFDA has accepted review of Dr. Reddy's 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to ORENCIA (abatacept) for multiple autoimmune indications, supported by analytical, PK and clinical data, including an ongoing Phase 3 trial (company announcement).Narratiefupdate • Feb 21
500124: Biosimilar Pipeline And New Launches Will Drive Future Upside
Analysts have nudged their fair value estimate for Dr. Reddy's Laboratories slightly higher from about ₹1,611 to roughly ₹1,615 per share, reflecting updated assumptions on revenue growth, profit margins, and the future P/E multiple in their models. What's in the News US FDA accepted review of a 351(k) Biologics License Application for DRL_AB, a proposed interchangeable biosimilar to Orencia (abatacept), for multiple rheumatoid and arthritis indications in adults and children, backed by analytical, PK, and clinical data including Phase 1 PK similarity and an ongoing Phase 3 trial (company announcement).Narratiefupdate • Feb 07
500124: Future Regulatory And Tax Compliance Risks Will Limit Upside Potential
Analysts have raised their fair value estimate for Dr. Reddy's Laboratories from ₹990 to ₹1,024, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E as key drivers of this change. What's in the News Launched OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent to Extra Strength Pataday Once Daily Relief, for temporary relief of itchy eyes caused by allergens.Narratiefupdate • Jan 23
500124: Biosimilar Approvals And New Launches Will Drive Future Upside
Analysts have trimmed their price target on Dr. Reddy's Laboratories slightly from ₹1,615 to about ₹1,611, reflecting updated views on future revenue growth, profit margins, and a higher assumed future P/E multiple. What's in the News Launched an over the counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S., a generic equivalent of Extra strength Pataday Once Daily Relief, targeting temporary relief of itchy eyes from allergens such as pollen, grass and animal dander (USFDA approval).Narratiefupdate • Jan 06
500124: Biosimilar Approvals Will Support Future Upside As Regulatory Issues Remain Contained
Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,615, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions that they view as offsetting each other. What's in the News Dr. Reddy's received five separate orders from the GST Authority for tax demand, interest, and penalties related to alleged excess input tax credit for FY2018-19 to FY2022-23, with penalties of ₹1,89,30,110, ₹80,41,186, ₹3,52,95,063, ₹1,45,04,023 and ₹70,86,675 respectively.Narratiefupdate • Dec 14
500124: Biosimilar Approvals Will Drive Future Upside Despite Slight Multiple Compression
Analysts have marginally lowered their price target on Dr. Reddy's Laboratories to ₹1,615 from ₹1,626, reflecting a slightly higher discount rate, while also factoring in stronger revenue growth, improved profit margins and a somewhat lower future P E multiple. What's in the News European Commission grants marketing authorization for AVT03, Dr. Reddy's and Alvotech's biosimilar to Prolia and Xgeva, with Dr. Reddy's holding exclusive commercialization rights in the U.S. and semi exclusive rights in Europe and the UK (company announcement) EMA's CHMP earlier issued a positive opinion recommending AVT03 for marketing authorization across the European Economic Area, with a separate submission planned to the UK MHRA under the International Recognition Procedure (company announcement) Dr. Reddy's receives an Establishment Inspection Report from the USFDA, with the inspection classified as Voluntary Action Indicated and officially closed (regulatory filing) Eisai and Dr. Reddy's reach a patent settlement allowing Dr. Reddy's to launch a generic version of cancer drug Lenvima in the U.S. from July 1, 2030, subject to certain contingencies (legal filing) Company launches Tegoprazan in India under the brand name PCAB to treat acid related gastrointestinal diseases, targeting a large and growing acid peptic disease population (product launch) Valuation Changes The fair value estimate has been reduced slightly to ₹1,615 from ₹1,625.93, reflecting a modestly more conservative outlook.Narratiefupdate • Oct 27
Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities
Analysts have revised their price target for Dr. Reddy's Laboratories upward from ₹1,287.37 to ₹1,300.62. This reflects renewed confidence driven by improved profit margin forecasts, despite marginally lower revenue growth expectations.Narratiefupdate • Sep 04
Investments In Biosimilars And NRT Will Expand Market Reach, Yet Regulatory Hurdles May Persist
With both revenue growth and net profit margin forecasts steady, analysts maintained their fair value estimate for Dr. Reddy's Laboratories at ₹1287. What's in the News Dr. Reddy's Laboratories and Extrovis AG launched Fluorouracil Cream, 0.5% in the US as an authorized generic, approved by the USFDA.
Nieuw narratief • Nov 13
Regulatory Hurdles And Rising Expenses Threaten To Squeeze Margins And Stifle Growth
Upfront costs from acquisitions and partnerships may pressure short-term earnings and compress net margins.Rendement voor aandeelhouders
| 500124 | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -0.2% | 2.3% | 1.8% |
| 1Y | 5.4% | 13.2% | -0.9% |
Rendement versus industrie: 500124 presteerde slechter dan de Indian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 13.2 % opleverde.
Rendement versus markt: 500124 overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van -0.9 %.
Prijsvolatiliteit
| 500124 volatility | |
|---|---|
| 500124 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.0% |
Stabiele aandelenkoers: 500124 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van 500124 is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1984 | 27,527 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited is, samen met haar dochterondernemingen, wereldwijd actief als een geïntegreerd farmaceutisch bedrijf. Het is actief in de segmenten Global Generics, Pharmaceutical Services and Active Ingredients (PSAI) en Others. Het segment Global Generics produceert en verkoopt farmaceutische producten op recept en vrij verkrijgbare farmaceutische producten die op de markt worden gebracht onder een merknaam of als een generieke einddosering met therapeutische gelijkwaardigheid aan merkformuleringen, en houdt zich ook bezig met biologische geneesmiddelen.
Dr. Reddy's Laboratories Limited Samenvatting
| 500124 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹1.14t |
| Inkomsten(TTM) | ₹42.85b |
| Inkomsten(TTM) | ₹335.93b |
26.3x
Koers/Winstverhouding3.4x
P/S-verhoudingIs 500124 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 500124 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹335.93b |
| Kosten van inkomsten | ₹158.67b |
| Brutowinst | ₹177.26b |
| Overige uitgaven | ₹134.41b |
| Inkomsten | ₹42.85b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Jul 22, 2026
| Winst per aandeel (EPS) | 51.46 |
| Brutomarge | 52.77% |
| Nettowinstmarge | 12.76% |
| Schuld/Eigen Vermogen Verhouding | 16.5% |
Hoe presteerde 500124 op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.6%
Huidig dividendrendement16%
UitbetalingsratioBetaalt 500124 een betrouwbaar dividend?
Zie 500124 dividendgeschiedenis en benchmarks| Dr. Reddy's Laboratories dividenddata | |
|---|---|
| Ex Dividend Datum | Jul 10 2026 |
| Betaaldatum dividend | Jul 30 2026 |
| Dagen tot Ex-dividend | 3 days |
| Dagen tot dividendbetaaldatum | 23 days |
Betaalt 500124 een betrouwbaar dividend?
Zie 500124 dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/07 11:40 |
| Aandelenkoers aan het einde van de dag | 2026/07/07 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Dr. Reddy's Laboratories Limited wordt gevolgd door 69 analisten. 37 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |